Chen Chih-Heng, Tsai Ping-Hsiu, Tsai Wan-Chuan, Ko Mei-Ju, Hsu Le-Yin, Chien Kuo-Liong, Hung Kuan-Yu, Wu Hon-Yen
Department of Medical Education, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Department of Family Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
J Nephrol. 2024 Nov;37(8):2113-2125. doi: 10.1007/s40620-024-02065-9. Epub 2024 Sep 28.
The benefits and harms of protein-restricted diets supplemented with ketoanalogues in patients with chronic kidney disease (CKD) remain uncertain. We aimed to evaluate the effects of ketoanalogues supplemented to protein-restricted diets in patients with advanced CKD.
We conducted systematic literature searches of PubMed, Embase, Scopus, and Cochrane Library up to June 3, 2024. Randomized controlled trials comparing ketoanalogue supplementation with a low- or very low-protein diet versus a low-protein diet alone in stages 3-5 CKD patients were selected. Outcomes included glomerular filtration rate (GFR), end-stage kidney disease (ESKD), all-cause mortality, and blood levels of urea nitrogen, calcium, phosphorus, and albumin. Triceps skin fold, mid-arm muscle circumference, lean body mass, and subjective global assessment were also evaluated. The protocol for this systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD42023465754).
A total of 16 trials comprising 1344 participants were identified, with a median follow-up of 13 months. Compared to a low-protein diet alone, ketoanalogues supplemented to a protein-restricted diet resulted in a significantly higher GFR, decreased levels of urea nitrogen and phosphorus, and increased levels of calcium. Furthermore, ketoanalogues combined with a protein-restricted diet showed a marginally lower risk of ESKD in participants without diabetes. No significant differences were observed in all-cause mortality, albumin, mid-arm muscle circumference, lean body mass, and subjective global assessment.
For stages 3-5 CKD patients, ketoanalogues combined with a protein-restricted diet may help postpone initiation of dialysis, improve calcium-phosphate homeostasis, and slow GFR decline, while maintaining a similar nutritional status and survival. Larger, long-term studies are needed to confirm these potential benefits, especially in CKD patients with diabetes.
对于慢性肾脏病(CKD)患者,补充酮类似物的蛋白质限制饮食的利弊仍不明确。我们旨在评估在晚期CKD患者中,补充酮类似物的蛋白质限制饮食的效果。
我们对截至2024年6月3日的PubMed、Embase、Scopus和Cochrane图书馆进行了系统的文献检索。选择了比较在3-5期CKD患者中补充酮类似物的低蛋白或极低蛋白饮食与单纯低蛋白饮食的随机对照试验。结局指标包括肾小球滤过率(GFR)、终末期肾病(ESKD)、全因死亡率以及血尿素氮、钙、磷和白蛋白水平。还评估了三头肌皮褶厚度、上臂中部肌肉周长、瘦体重和主观全面评定。本系统评价的方案已在国际前瞻性系统评价注册库(PROSPERO;注册号CRD42023465754)中注册。
共确定了16项试验,包括1344名参与者,中位随访时间为13个月。与单纯低蛋白饮食相比,补充酮类似物的蛋白质限制饮食可使GFR显著升高,尿素氮和磷水平降低,钙水平升高。此外,在无糖尿病的参与者中,酮类似物与蛋白质限制饮食联合使用显示ESKD风险略低。在全因死亡率、白蛋白、上臂中部肌肉周长、瘦体重和主观全面评定方面未观察到显著差异。
对于3-5期CKD患者,酮类似物与蛋白质限制饮食联合使用可能有助于推迟透析开始时间,改善钙磷稳态,减缓GFR下降,同时维持相似的营养状况和生存率。需要开展更大规模的长期研究来证实这些潜在益处,尤其是在糖尿病CKD患者中。